Sai Parenterals to acquire majority stake in Bion Therapeutics in all cash deal | Hyderabad News

Sai Parenterals Limited is acquiring a majority stake in Hyderabad-based branded formulations prescription business Bion Therapeutics India Ltd through its wholly owned subsidiary, SP Analytics Private Limited, for an undisclosed sum. The Hyderabad-based Sai Parenterals has already signed a definitive agreement for the all-cash transaction that is expected to close before the end of the month.On completion, Bion will become a step-down subsidiary of Hyderabad-based Sai Parenterals. The proposed acquisition will bring to Sai Parenterals 16 established prescription brands, about 250 field staff, access to nearly 20,000 doctors and a distribution network covering more than 17,000 retailers across 12 states, primarily in South, East and Northeast India.Founded in 2005, Bion operates in niche therapeutic areas including neuropathy, diabetes supportive care, mitochondrial health, wound care and pain management. Its key brands include Meaxon, MITOQ7, Adgaba, Sunlite and LG Bion.The company’s doctor-led model is built on direct speciality engagement rather than trade-led generic sales, giving its brands prescriber recall and loyalty, Sai Parenterals said.Sai Parenterals said Bion’s portfolio, currently manufactured through contract partners, will progressively move to its own TGA-Australia- and WHO-GMP-accredited facilities, improving supply assurance, quality control and margins.The acquisition also gives Sai Parenterals a commercial platform for its Sai Prathyak Laboratories R&D portfolio of 174 molecules and 285 SKUs, as well as selected products from Noumed’s library of more than 511 TGA-approved dossiers, subject to Indian approvals.Bion’s existing management, led by its managing director Laxman Prasad Shukla, will continue to run the business after completion. The transaction will be funded through internal accruals, debt and a GCP allocation.
Source link



